Recombinant Humanized antibody to Human GPC3
Figure 1 IA/L of serum was plotted following injection of 10 mg I-124 codrituzumab alone (circle) or co-infused with 2.5 mg/kg (triangles) or 5 mg/kg (squares).
The larger mass amount of antibody resulted in significant mass-dependent changes with longer half-life and greater AUC than the 10 mg injection (Table 2). There was an overlap of the clearance curves for the 2.5 and 5 mg/kg co-infused mass.
Figure 2 Distributions of CD16 MESF across different GPC3 IHC scores.
It was also noted that the distributions of CD16 MESF across the four different GPC3 IHC categories (0, 1+, 2+, and 3+) are not significantly different.
Figure 3 Kaplan-Meier curves by joint GPC3 IHC high/low and CD16 MESF high/low status, where a GPC3-IHC high level is defined by GPC3 IHC = 2+, 3+, and a CD16-MESF high level is defined by CD16 MESF ≥ the median (363,594 MESF).
(A, B) Association between CD16 MESF level and codrituzumab treatment effect given a high level of GPC3 IHC. (C, D) Association between CD16 MESF level and codrituzumab treatment effect given a low level of GPC3 IHC.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Codrituzumab.
Afuco™ Anti-GPC3 ADCC Therapeutic Antibody (Codrituzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized antibody to Human GPC3
For Research Use Only. Not For Clinical Use.